Trial Profile
An Exploratory Study of the Biologic Effects and Biomarkers of Nivolumab in Combination With Ipilimumab in Subjects With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Sep 2023
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms CheckMate 592
- Sponsors Bristol-Myers Squibb
- 06 Jun 2023 The trial has been completed in Spain, according to European Clinical Trials Database record.
- 06 Jun 2023 The trial has been completed in Germany, according to European Clinical Trials Database record.
- 04 Jun 2023 The trial has been completed in Netherlands, according to European Clinical Trials Database record.